Bioventix PLC (AIM:BVXP)

Bioventix Income Statement

Financials in millions GBP. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Revenue	13.12	13.61	12.82	11.72	10.93
Revenue Growth (YoY)	-3.61%	6.17%	9.36%	7.22%	5.98%
Cost of Revenue	1.2	0.93	0.83	0.71	0.82
Gross Profit	11.92	12.68	11.99	11.01	10.11
Selling, General & Admin	2.05	1.99	1.77	1.61	1.51
Research & Development	-0.3	-0.03	-0.03	-0.02	-0.03
Operating Expenses	1.84	2.05	1.92	1.83	1.73
Operating Income	10.07	10.63	10.07	9.18	8.38
Interest Expense	-	-	-	-0	-
Interest & Investment Income	0.19	0.2	0.1	0	0.03
Currency Exchange Gain (Loss)	-0.17	-0.04	-0.04	0.09	-0.29
EBT Excluding Unusual Items	10.1	10.79	10.13	9.28	8.12
Gain (Loss) on Sale of Investments	-	-0.18	-	-	-
Pretax Income	10.1	10.6	10.13	9.28	8.12
Income Tax Expense	2.51	2.51	1.76	1.6	1.39
Net Income	7.58	8.1	8.37	7.67	6.73
Net Income to Common	7.58	8.1	8.37	7.67	6.73
Net Income Growth	-6.33%	-3.29%	9.10%	14.01%	-6.54%
Shares Outstanding (Basic)	5	5	5	5	5
Shares Outstanding (Diluted)	5	5	5	5	5
Shares Change (YoY)	-0.08%	0.14%	0.56%	-0.03%	0.76%
EPS (Basic)	1.45	1.55	1.61	1.47	1.29
EPS (Diluted)	1.43	1.53	1.58	1.46	1.28
EPS Growth	-6.26%	-3.42%	8.48%	14.04%	-7.24%
Free Cash Flow	7.01	8.33	7.79	7.55	6.08
Free Cash Flow Per Share	1.32	1.57	1.47	1.44	1.16
Dividend Per Share	1.500	1.550	1.520	1.260	1.050
Dividend Growth	-3.23%	1.97%	20.64%	20.00%	19.32%
Gross Margin	90.86%	93.20%	93.54%	93.94%	92.52%
Operating Margin	76.80%	78.10%	78.57%	78.34%	76.68%
Profit Margin	57.83%	59.51%	65.33%	65.48%	61.58%
Free Cash Flow Margin	53.47%	61.21%	60.80%	64.38%	55.60%
EBITDA	10.17	10.74	10.2	9.32	8.52
EBITDA Margin	77.51%	78.93%	79.58%	79.56%	77.92%
D&A For EBITDA	0.09	0.11	0.13	0.14	0.14
EBIT	10.07	10.63	10.07	9.18	8.38
EBIT Margin	76.80%	78.10%	78.57%	78.34%	76.68%
Effective Tax Rate	24.88%	23.64%	17.39%	17.29%	17.08%

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.